Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Derek Damin

Allergy & Immunology Nashville, TN Medical Doctor

NPI 1003809724 CMS profile 134

3601 The Vanderbilt Clinic, Nashville, TN 37232

Open in the dashboard

General payments

$43,855

325 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Derek Damin of Nashville, TN is reported in the CMS Open Payments database as having received $43,855 across 325 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $4,269 72
2021 General $14,957 97
2020 General $12,949 73
2019 General $11,680 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Derek Damin
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Derek Damin were reported at $0. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Derek Damin Allergy & Immunology median Middle half National median
2019 $11,680 $594 $163–$1,512 $163
2020 $12,949 $426 $106–$1,233 $114
2021 $14,957 $638 $157–$1,708 $132
2022 $4,269 $790 $205–$1,961 $149
2023 $0 $852 $220–$2,147 $160
2024 $0 $865 $203–$2,267 $164
2025 $0 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Regeneron Healthcare Solutions, Inc. $24,660 75 payments
  2. Grifols USA, LLC $11,436 12 payments
  3. Genzyme Corporation $3,062 10 payments
  4. AstraZeneca Pharmaceuticals LP $1,096 41 payments
  5. CSL Behring $1,017 50 payments
  6. kaleo, Inc. $497 35 payments
  7. Pfizer Inc. $305 10 payments
  8. GlaxoSmithKline, LLC. $290 20 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $281 18 payments
  10. Shire North American Group Inc $254 5 payments
  11. Other $956 49 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $32,430 22 payments
  2. Food and Beverage $5,941 281 payments
  3. Consulting Fee $3,780 2 payments
  4. Travel and Lodging $1,445 14 payments
  5. Education $234 5 payments
  6. Honoraria $25 1 payment
Products named General payments · program years 2019–2022
  1. DUPIXENT Inflammation And Immunology $24,660 75 payments
  2. Xembify $9,532 10 payments
  3. DUPIXENT Immunology $3,093 12 payments
  4. Gamunex-C $1,905 2 payments
  5. Haegarda $601 26 payments
  6. FASENRA Respiratory $589 17 payments
  7. AUVI-Q $497 35 payments
  8. Hizentra $416 24 payments
  9. FASENRA Respiratory $408 18 payments
  10. CUVITRU $223 13 payments
  11. Other $2,162 112 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

598

Median for Allergy/ Immunology: 449

Drug cost

$932,657

Median for Allergy/ Immunology: $169,700

Branded share of claims

43.5%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Haegarda C1 Esterase Inhibitor Brand 19 $630,291
Dupixent Pen Dupilumab Brand 44 $167,218
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 60 $51,397
Icatibant Icatibant Acetate Brand 12 $48,665
Spiriva Respimat Tiotropium Bromide Brand 11 $7,060
Wixela Inhub Fluticasone Propion/Salmeterol Brand 39 $6,880
Epinephrine Generic 29 $6,150
Azelastine Hcl Generic 131 $4,944
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 19 $4,391
Albuterol Sulfate Hfa Albuterol Sulfate Brand 45 $1,687

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$61,140

Medicare's payments for the services billed

Medicare patients

128

Average age 71

Services billed

1,397

79 women, 49 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 53%
Ischemic heart disease 31%
Diabetes 29%
Depression 21%
Osteoporosis 18%
Chronic kidney disease 16%
COPD 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

325 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record